When Colorectal Cancer Comes Back: Recurrence Questions

Colorectal cancer that returns is not automatically incurable. That is the single most important thing to establish, and it changes the whole conversation.

NCI's clinical summary gives a number for liver spread. When the metastases can be removed with clear margins, 5-year survival ran 25% to 40%. Most of those studies were not randomized.

The picture is not fixed at the first assessment. Several studies used combination chemotherapy on liver-only disease once judged unremovable. Some of it became removable. People who convert that way have 5-year survival close to those whose disease was removable from the start.

Lung spread matters too. NCI notes that limited lung spread may be considered for surgery. So may spread to both lung and liver. Five-year survival is possible in carefully selected cases.

Questions that follow:

• Is my recurrence in one organ or several?
• Has a liver surgeon reviewed my scans, not only a medical oncologist?
• If it is not removable now, is there a chemotherapy plan aimed at making it removable?

NCI adds one caution here. No consensus exists on the best regimen for turning unremovable liver metastases into removable ones. So the answer may reasonably differ between centers.

Carcinoembryonic antigen, or CEA, is a blood protein used in colon cancer follow-up. It is also widely misread. NCI's review of the marker is specific on three points:

• CEA is not a useful screening test for colorectal cancer. There are too many false-positive and false-negative results.
• CEA testing after surgery is meant for people who could have surgery on liver or lung metastases.
• Using CEA levels alone to track response to treatment is not recommended.

That last point is worth sitting with. If your CEA moved and the plan changed on that alone, it is fair to ask what imaging confirmed it.

A related fact belongs here: a raised CEA level before treatment carries a worse prognosis. That is different from a rising CEA during follow-up.

NCI is direct about the gap. Limited data and no high-level evidence guide follow-up after surgery and adjuvant therapy. What exists are recommendations from the American Society of Clinical Oncology and the National Comprehensive Cancer Network.

So the schedule you are given is a considered protocol, not a proven one. Reasonable questions:

• Which guideline is my follow-up schedule based on?
• What scans, blood tests, and colonoscopies does it include, and at what intervals?
• What finding would move me from surveillance to treatment?

For recurrent or metastatic disease, tumor testing decides much of what is available. Ask which of these has been run.

Mismatch repair and microsatellite status. About 4% of stage IV colorectal cancers are mismatch repair deficient, also called microsatellite instability-high. Two test methods are used. One is molecular genetic testing on tumor tissue. The other is immunohistochemistry, which looks for loss of mismatch repair proteins. The pattern is linked to inherited changes in MLH1, MSH2, MSH6, and PMS2. Those are the genes behind Lynch syndrome. It can also arise when one of those genes is switched off by DNA methylation.

Since 2015, this result has also predicted response to immunotherapy. KEYNOTE-177 enrolled 307 people with untreated MSI-H or dMMR metastatic disease. Half got pembrolizumab by drip every 3 weeks. Half got chemotherapy. Median progression-free survival was 16.5 months versus 8.2 months. Grade 3 or higher side effects hit 56% on pembrolizumab and 78% on chemotherapy.

FDA approved pembrolizumab for untreated metastatic dMMR or MSI-H colorectal cancer in 2020. Earlier, in 2017, it approved pembrolizumab and nivolumab for microsatellite-unstable tumors. Those patients had already had fluorouracil, oxaliplatin, and irinotecan-based therapy.

BRAF V600E. This appears in about 10% of metastatic colorectal cancers and signals a worse outlook. NCI notes that unlike in melanoma, a BRAF inhibitor alone has not helped in colorectal cancer.

The BEACON trial enrolled 665 previously treated people. One arm took encorafenib tablets daily by mouth, at the trial's standard 300 mg, alongside cetuximab given by vein — a larger first infusion, then weekly ones. If encorafenib is on the table for you, the daily amount your oncologist writes is the one that counts, since it is reduced for side effects. Median survival was 9.3 months, against 5.9 months in the control arm. Grade 3 or higher side effects hit 50% on the two-drug regimen. FDA approved encorafenib with cetuximab for this group.

KRAS and NRAS. These affect whether EGFR-directed drugs will work. In KEYNOTE-177, the subgroup with KRAS or NRAS variants was the one where the hazard ratio did not favor pembrolizumab.

Recurrence gets used loosely, and it covers several different situations. Pinning down which one you have changes everything that follows.

A tumor at the site of the original surgery is a local recurrence. A tumor in the liver or lung is distant spread. A new primary colon cancer somewhere else in the bowel is a third thing again, and it is treated as a new diagnosis rather than a return.

Ask the team to say which of the three your imaging shows. Ask whether a biopsy is planned to confirm it, and whether that tissue will be sent for the molecular tests described above. Tumor biology can shift between the first diagnosis and a recurrence, so results from years ago may not still apply.

About the family. A mismatch repair deficient result can point to Lynch syndrome, which affects blood relatives. Ask whether genetic counseling is indicated and who arranges it.

About the sequence. Ask what comes after the treatment being started, and whether starting one drug closes off another later.

About local options. Surgery is not the only local tool. NCI lists embolization and interstitial radiation therapy for liver metastases. Ask whether an interventional radiologist has looked at your case.

A recurrence lands differently from the first diagnosis. You already know what treatment feels like. Our page on fear of recurrence covers what tends to help.

For what recurrence means in general, see when cancer comes back. For the disease overview, see colorectal cancer.

A recurrence workup can take weeks. These symptoms should not wait for the next scan or the next appointment.

• Call 911 or go to an emergency department if you have cramping belly pain with vomiting, a swollen belly, and you cannot pass gas or stool. A tumor at the old surgical site can block the bowel, and that needs treating the same night.
• Call 911 or go to an emergency department if you pass a lot of blood from the back passage, or your stools are black and tarry.
• Call 911 or go to an emergency department if you get sudden breathlessness or chest pain. Cancer raises the risk of a clot on the lung, and lung spread can show up this way.
• Call your care team the same day if the whites of your eyes or your skin turn yellow, your urine goes dark, or you get pain under your right ribs. Liver metastases can block the flow of bile.
• Call your care team the same day if one calf becomes swollen, warm, and painful.
• Call your oncology team straight away, day or night, if you have a temperature of 100.4°F (38°C) or higher while you are on chemotherapy. CDC is blunt about this one: with your white cells low, that fever is a medical emergency. Use the after-hours number rather than waiting for the clinic to open, and if nobody answers quickly, go to an emergency department and say you are on chemotherapy.
• Call your care team within a day or two if belly or pelvic pain is new and will not settle, if your bowel pattern changes and stays changed, or if you are losing weight without trying. Say plainly that you have had colorectal cancer before, so the call is routed to the right person.

• MedlinePlus, Intestinal obstruction and ileus; accessed August 11, 2026
• National Cancer Institute, Colon Cancer Treatment PDQ, health professional version, updated February 12, 2025; accessed August 6, 2026
• Centers for Disease Control and Prevention, Fever and cancer treatment; accessed August 13, 2026